© American Society of Transplantation and the American Society of Transplant Surgeons.Published by Wiley .This is the peer reviewed version of the following article: Am J Transplant. 2020 ; 20, which has been published in final form at https://doi.org/10.1111/ajt.15769. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving
Am J Transplant. 2020 ;20:1629-1641.
Treatment of carbapenemase-producing Enterobacterales bloodstream infections in solid organ transplant recipients is challenging. The objective of this study was to develop a specific score to predict mortality in solid organ transplant recipients with carbapenemase-producing Enterobacterales bloodstream infections. A multina-tional, retrospective (2004-2016) cohort study (INCREMENT-SOT, ClinicalTrials.gov NCT02852902) was performed. The main outcome variable was 30-day all-cause mor-tality. The INCREMENT-SOT-CPE score was developed using logistic regression. The global cohort included 216 patients. The final logistic regression model included the fol-lowing variables: INCREMENT-CPE mortality score ?8 (8 points), no source control (3 points), inappropriate empirical therapy (2 points), cytomegalovirus disease (7 points), lymphopenia (4 points), and the interaction between INCREMENT-CPE score ?8 and CMV disease (minus 7 points). This score showed an area under the receiver operat-ing characteristic curve of 0.82 (95% confidence interval [CI] 0.76-0.88) and classified patients into 3 strata: 0-7 (low mortality), 8-11 (high mortality), and 12-17 (very-high mortality). We performed a stratified analysis of the effect of monotherapy vs combi-nation therapy among 165 patients who received appropriate therapy. Monotherapy was associated with higher mortality only in the very-high (adjusted hazard ratio [HR] 2.82, 95% CI 1.13-7.06, P = .03) and high (HR 9.93, 95% CI 2.08-47.40, P = .004) mortal-ity risk strata. A score-based algorithm is provided for therapy guidance.
